{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:07:45Z","timestamp":1790208465781,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.vaccine.2023.10.031","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T23:47:58Z","timestamp":1701820078000},"page":"396-401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immunogenicity and safety of a live-attenuated varicella vaccine in a healthy population aged 13\u00a0years and older: A randomized, double-blind, controlled study"],"prefix":"10.1016","volume":"42","author":[{"given":"Lili","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiebing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningning","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangyang","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxue","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangwei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9660-0216","authenticated-orcid":false,"given":"Changgui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunfang","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaru","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.10.031_b0005","doi-asserted-by":"crossref","first-page":"15016","DOI":"10.1038\/nrdp.2015.16","article-title":"Varicella zoster virus infection","volume":"1","author":"Gershon","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.vaccine.2023.10.031_b0010","unstructured":"Lopez A, Harrington T, Marin M. Pink Book: Varicella (14th edition); 2021."},{"issue":"10","key":"10.1016\/j.vaccine.2023.10.031_b0015","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1080\/21645515.2018.1480283","article-title":"Update on trends in varicella mortality during the varicella vaccine era-United States, 1990\u20132016","volume":"14","author":"Leung","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.10.031_b0020","first-page":"403","article-title":"Epidemiological characteristics of varicella in China, 2016\u20132019","volume":"26","author":"Dong","year":"2020","journal-title":"Chinese J Vac Immun"},{"key":"10.1016\/j.vaccine.2023.10.031_b0025","unstructured":"Chinese Center for Disease Control and Prevention. Infectious Disease Surveillance Report (2021, in Chinese)."},{"key":"10.1016\/j.vaccine.2023.10.031_b0030","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1542\/peds.2010-0962","article-title":"Varicella-related hospitalizations in the United States, 2000\u20132006: the 1-dose varicella vaccination era","volume":"127","author":"Lopez","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2023.10.031_b0035","doi-asserted-by":"crossref","first-page":"S407","DOI":"10.1093\/infdis\/jiac242","article-title":"Decline in severe varicella disease during the United States varicella vaccination program: hospitalizations and deaths, 1990\u20132019","volume":"226","author":"Marin","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.10.031_b0040","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/21645515.2020.1769395","article-title":"Epidemiology of varicella and effectiveness of varicella vaccine in Hangzhou, China, 2019","volume":"17","author":"Xu","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.10.031_b0045","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1186\/s12879-021-06217-1","article-title":"Two-dose varicella vaccine effectiveness in China: a meta-analysis and evidence quality assessment","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2023.10.031_b0050","article-title":"Beijing varicella vaccine recommendations (in Chinese)","volume":"47","author":"Beijing Center for Disease Control and Prevention","year":"2013","journal-title":"Chinese J Prevent Med"},{"key":"10.1016\/j.vaccine.2023.10.031_b0055","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1097\/INF.0b013e31828b7def","article-title":"Primary versus secondary failure after varicella vaccination: implications for interval between 2 doses","volume":"32","author":"Bonanni","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2023.10.031_b0060","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1600-0609.2004.00216.x","article-title":"Immunogenicity of a two-dose regime of varicella vaccine in children with cancers","volume":"72","author":"Leung","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.vaccine.2023.10.031_b0065","doi-asserted-by":"crossref","unstructured":"Kuter BJ, Ngai A, Patterson CM, Staehle BO, Cho I, Matthews H, et al. the Oka\/Merck Varicella Vaccine Study, G. Safety, tolerability, and immunogenicity of two regimens of Oka\/Merck varicella vaccine (Varivax\u00ae) in healthy adolescents and adults. Vaccine 1995;13:967\u2013972. doi:10.1016\/0264-410X(95)00046-4.","DOI":"10.1016\/0264-410X(95)00046-4"},{"key":"10.1016\/j.vaccine.2023.10.031_b0070","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1080\/21645515.2018.1551701","article-title":"Safety, immunogenicity, and lot-to-lot consistency of live attenuated varicella vaccine in 1\u20133 years old children: a double-blind, randomized phase III trial","volume":"15","author":"Huang","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.10.031_b0075","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.cmi.2018.12.033","article-title":"Efficacy, safety and immunogenicity of live attenuated varicella vaccine in healthy children in China: double-blind, randomized, placebo-controlled clinical trial","volume":"25","author":"Hao","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2023.10.031_b0080","article-title":"Immunogenicity and safety of a booster dose of live attenuated varicella vaccine, and immune persistence of a primary dose for children aged 2 to 6 years","volume":"10","author":"Zhang","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2023.10.031_b0085","doi-asserted-by":"crossref","first-page":"2161789","DOI":"10.1080\/21645515.2022.2161789","article-title":"Immunogenicity and safety of a live attenuated varicella vaccine co-administered with inactive hepatitis A vaccine: A phase 4, single-center, randomized, controlled trial","volume":"19","author":"Sun","year":"2023","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2023.10.031_b0090","first-page":"63","article-title":"The immunogenicity and safety of two-dose schedule of varicella live-attenuated vaccine in healthy population aged \u226513 years old in a non-inferiority clinical trial (in Chinese)","volume":"25","author":"Liu","year":"2019","journal-title":"Chinese J Vacc Immuniz"},{"key":"10.1016\/j.vaccine.2023.10.031_b0095","unstructured":"National Medical Products Administration. The guidance principle of grade standard for adverse reactions that occur in clinical trial of prevention vaccines (in Chinese). Register no. 102. 2019, Beijing China: NMPA."},{"key":"10.1016\/j.vaccine.2023.10.031_b0100","unstructured":"National Medical Products Administration. Guidelines for comparable clinical trials of prophylactic vaccines (in Chinese). Register no. 94. 2019, Beijing China: NMPA."},{"key":"10.1016\/j.vaccine.2023.10.031_b0105","first-page":"604","article-title":"Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989","volume":"87","author":"White","year":"1991","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2023.10.031_b0110","doi-asserted-by":"crossref","unstructured":"Reynolds MA, Kruszon-Moran D, Jumaan A, Schmid DS, McQuillan GM. Varicella seroprevalence in the U.S.: data from the National Health and Nutrition Examination Survey, 1999-2004. Public health reports (Washington, D.C.: 1974) 2010;125:860-869, doi:10.1177\/003335491012500613.","DOI":"10.1177\/003335491012500613"},{"key":"10.1016\/j.vaccine.2023.10.031_b0115","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1017\/S0950268804003140","article-title":"Seroprevalence of antibody to varicella zoster virus in England and Wales in children and young adults","volume":"132","author":"Vyse","year":"2004","journal-title":"Epidemiol Infect"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2023.10.031_b0120","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1086\/522130","article-title":"Humoral and cell-mediated immune responses in children and adults after 1 and 2 doses of varicella vaccine","volume":"197","author":"Watson","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.10.031_b0125","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1016\/j.vaccine.2021.03.056","article-title":"The impact of two-dose varicella vaccination on varicella and herpes zoster incidence in South Korea using a mathematical model with changing population demographics","volume":"39","author":"Suh","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.10.031_b0130","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1016\/j.vaccine.2006.06.030","article-title":"Safety, tolerability, and immunogenicity of a two-dose regimen of high-titer varicella vaccine in subjects > or =13 years of age","volume":"24","author":"Diaz","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.10.031_b0135","first-page":"970","article-title":"Postpartum varicella vaccination: is the vaccine virus excreted in breast milk?","volume":"102","author":"Bohlke","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2023.10.031_b0140","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12882-018-0976-4","article-title":"Varicella infections in patients with end stage renal disease: a systematic review","volume":"19","author":"Ong","year":"2018","journal-title":"BMC Nephrol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23012124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23012124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T14:57:20Z","timestamp":1715180240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23012124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0264410X23012124"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.10.031","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of a live-attenuated varicella vaccine in a healthy population aged 13\u00a0years and older: A randomized, double-blind, controlled study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.10.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}